Introduction
Due to developments of highly active antiretroviral therapy (HARRT), morbidity and mortality related to human immunodeficiency virus (HIV) infected patients has reduced markedly [1, 2] . In 2014, the number of HIV-infected patients globally was about 36.9 million (34.3 -41.4 million), and 2 million people were newly diagnosed with HIV [3] . At this time, 15 million HIV patients were receiving HAART [3] . Previous studies have found that starting HAART when the CD4+ cell count is high is recommended for improved virologic and immunologic recovery and prevents disease progression [4] [5] [6] . Starting HAART when CD4+ cell counts are already low results in acquired immunodeficiency syndrome (AIDS) defining disease for many patients [7] ; HIV-infected patients who started HAART with a CD4+ cell count <200 cells/mm 3 may not reach a normal CD4+ cell count [6] . In addition, early treatment of HAART prevents sexual transmission among serodiscordant couples [8] . Considering these clinical findings, many HIV/ AIDS expert groups have updated their clinical guidelines regarding the recommended time point for initiating HAART. The European AIDS Clinical Society (EACS) recommends that patients whose CD4+ cell counts are <350 cells/mm 3 initiate HAART [9] . However, the Department of Health and Human Services (DHHS) guidelines strongly recommend that HIV-positive patients with CD4+ cell count ≤500 cells/mm 3 should initiate HAART [10] . The World Health Organization (WHO) also recently updated their treatment guidelines to advise that HAART should be initiated for all HIV-positive adult patients, regardless of WHO clinical stage and CD4+ cell count [11] . Consistent with these other recommendations, the Korean Society for AIDS revised their guidelines in 2013 to recommend that all HIV-infected patients, regardless of CD4+ cell count, initiate HAART. The guidelines also favor treatment of HIV-positive patients whose infection status is acute or who were recently infected [12] . Although previous clinical data and guidelines recommend early initiation of ART, most HIV-infected patients initiate HAART when they are diagnosed with low CD4+ cell counts [2, 13, 14] . In Korea, the total number of patients infected with HIV in 2015 was 10,502 and there were 1,052 newly infected patients; incidence has been observed to be increasing steadily. In addition, with the support of the national HIV/AIDS policy, the proportion of patients treated with HAART has increased. It is necessary to know the real status of CD4+ cell count and HIV-RNA at the HIV diagnosis and HAART initiation. Therefore, we researched CD4+ cell count and HIV-RNA of Korean HIV-infected patients at the time points of diagnosis and initiation of treatment, using Korea HIV/AIDS Cohort Study data.
Materials and Methods
The Korea HIV/AIDS Cohort Study was a prospective observational cohort study with patients from 21 tertiary or secondary hospitals in South Korea, initiated in 2006. The Korea HIV/ AIDS Cohort Study collected data on HIV-infected individuals, including socioeconomic status, route of infection, HAART, conventional laboratory data, immunological and viral laboratory data, and information on opportunistic infections. The institutional review board approval was obtained from all participating hospitals.
Within the cohort study population, patients who had CD4+ cell count and HIV-RNA titer data at the time of diagnosis and HAART initiation were included in this study. Data were stratified on the basis of CD4+ cell count (≤100, However, in the three most recent years (2013) (2014) (2015) , the proportion of patients with lower initial CD4+ cell counts decreased. Additionally, the number of patients with CD4+ cell counts of more than 350 cells/mm 3 at the time of diagnosis has increased ( Fig. 1 ). However, patients with CD4+ cell counts lower than 100 cells/mm 3 at diagnosis were still a substantial portion (10-33%) of the cohort study population ( A total of 1,079 HIV-infected patients met the criteria for analysis of HIV-RNA titer at the time of diagnosis. Mean and median values of HIV-RNA titer were 394,955 copies/mL and 39,436 copies/mL (IQR, 7,150-151,000 copies/mL), respectively. Until the 2010-2012 period, the proportion of patients with HIV-RNA <50,000 copies/mL decreased (Fig. 2) . (Table 3) . The overall trend found was that the proportion of patients whose CD4+ cell count at initiation of HAART was over 350 cells/mm 3 has decreased (Fig. 3) , whereas, the proportion of patients with CD4+ cell counts lower than 350 cells/mm 3 at initiation of HAART has increased. In addition, the proportion of patients with CD4+ cell counts lower than 100 cells/mm 3 at initiation of HAART has increased; in 2010-2012 period, those patients account for 43% (Fig. 3) . CD4+ cell counts lower than 200 cells/mm 3 at initiation of HAART showed increasing tendency (30-65%, maximum at 2010-2012 period). A total of 322 HIV-infected patients met the criteria for anal- 
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ysis of HIV-RNA titers at initiation of HAART. The mean and median values of HIV-RNA titers were 493,116 copies/mL and 83,500 copies/mL (IQR, 15,763-292,500 copies/mL), respectively. The proportion of patients with HIV-RNA <50,000 copies/mL has steadily decreased, and patients with high RNA titer at treatment has increased (Fig. 4) .
Discussion
Based on Korea HIV/AIDS Cohort Study data, we found from our analysis that patients whose CD4+ cell count at the time of diagnosis was lower than 350 cells/mm 3 accounted for , which was lower than in our report [18] .
Our study showed that many patients initiated HAART at a low CD4+ cell count. The proportion of patients with a low CD4+ cell count at time of HAART initiation gradually increased until recently. We think that this result is influenced by an increase in patients with low CD4+ cell count at the time of diagnosis. More patients with CD4+ cell count ≤100 cells/ µL at time of diagnosis have been observed, and this tendency has increased over time.
In contrast to our national trends, recent reports from Asia showed a tendency towards increased CD4+ cell count at initiation of treatment. The TAHOD-TASER Cohort Study reported trends of CD4+ cell count at the initiation of HAART over time. Before 2010, median CD4+ cell count at the start of treatment was lower than 200 cells/mm 3 [20] . In these three studies, the proportion of patients with CD4+ cell count <200 cells/mm 3 at HAART initiation, after 2010, was similar to our findings. However, the findings showed improvement in CD4+ cell counts at HAART initiation, which was in contrast to what we observed in our cohort data. Research from industrialized countries show a stable median CD4+ cell count over 300 cells/mm 3 at
HAART initiation for a period of about twenty years [21, 22] . In this study, consistent low median CD4+ cell counts have been observed, which were lower than those observed in other developed countries. Upon comparing the factors based on the CD4+ cell count at diagnosis (cutoff point: 200 cells/mm 3 or 350 cells/mm 3 ), the median age at diagnosis was higher in patients with a low CD4+ cell count than in patients with a high CD4+ cell count. In addition, between 2001 and 2012, the median age at diagnosis for each period was high. Among the associated risk factors, a history of tuberculosis was observed more frequently in patients with a low CD4+ cell count. This finding may be associated with the risk of opportunistic tuberculous infection. Moreover, sexual contact among males and a history of syphilis were more frequently recorded in patients with a high CD4+ cell count. This finding suggests that the opportunity of diagnostic test would have influenced the rate of low CD4+ cell count at diagnosis. Our study has limitations. The size of the study population, when divided into each three-year interval time period, was small. However, we believe our cohort data provides an understanding of early-stage immune status of Korean HIV patients, as well as CD4+ status at initial treatment.
In summary, the Korea HIV/AIDS Cohort Study population comprised patients who had CD4+ cell count and HIV-RNA titer values at the time of diagnosis and initiation of HAART. Our findings, based on analysis of cohort study data, suggest that early detection of HIV patients and earlier initiation of HAART, to treat and prevent the spread of HIV infection, is needed.
